Stock Taper
SCREENER COMPARE ANY 2 STOCKS
SCTX
SCRIBE THERAPEUTICS INC.
NASDAQ
$34.13
▲ UP 3.96% (1.30)

KEY STATISTICS

Market Cap$552.29 M
52w High$39.60
52w Low$17.31
Dividend Yield—
Frequency—
P/E—
Volume179.58K
Shares Out.16.18M

COMPANY

LEADERSHIP

Benjamin L. Oakes
CHIEF EXECUTIVE
Benjamin L. Oakes

ABOUT

SECTOR
Healthcare
WENT PUBLIC
July 24, 2026
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
89

PRICE TARGET

Target High$60.00
Target Low$37.00
Target Median$50.00
Target Consensus$49.00

UPCOMING EARNINGS

DateSep 2, 2026
DayWednesday
Rev. Est.$3.11M
SEP
2
WED

PRICE

$34.13 ▲ UP 3.96% (+$1.30)
$34.50$35.259:30 AM10:35 AM11:40 AM12:44 PM1:49 PM2:54 PM3:59 PM34.13

About Scribe Therapeutics Inc.

http://www.scribetx.com ↗

Scribe Therapeutics is a clinical-stage biotech developing in vivo CRISPR-based genetic medicines targeting disease drivers, initially focusing on preventing atherosclerotic cardiovascular disease.

INDUSTRY

Biotechnology

A SERVICE SCRIBE THERAPEUTICS INC. IS KNOWN FOR

STX-1150

STX-1150, Scribe Therapeutics' lead CRISPR-based gene therapy, aims to epigenetically silence PCSK9 to reduce LDL cholesterol, currently in Phase 1 for cardiovascular disease.

COMPETITORS

COMPETITOR
BEAM COMPARE
CRBU COMPARE
CRSP COMPARE
EDIT COMPARE
NTLA COMPARE

ETFS HOLDING THIS STOCK

ETFS HOLDING
16
LISTED HERE
4
RANKED BY POSITION SIZE
ARKG
0.64% · 370.8K
VTI
0.00% · 15.5K
HL
HLTH
0.77% · 1.1K
TNXT
0.07% · 376

INSIDER TRADES

★
10 PERCENT OWNER
ELI LILLY & Co
— · —
2026-07-23